Diagnostic criteria of cachexia and their assessment: decreased muscle strength and fatigue

Purpose of reviewThe classification of cachexia or wasting disease is currently being revised to improve clinical trial design and clinical care. Decreased muscle strength and fatigue are proposed as diagnostic criteria for cachexia or wasting disease including, but not limited to, cancer. This review discusses their expected value in cancer cachexia. Recent findingsFatigue is frequent and multifactorial in cancer patients with limited value to predict cachexia, however, most cachectic patients have fatigue. Its assessment requires multimodal subjective instruments, for outcome monitoring many other fatigue cofactors need to be controlled. Cachexia seems a dominant cause for decreased muscle strength. Most cachectic patients lose muscle strength, usually together with reduced muscle mass. High-individual variability of muscle strength limits its use to longitudinal monitoring. Physical activity monitoring, applying also body-worn sensors, offers additional monitoring tools. SummaryTo diagnose and monitor cachexia, muscle strength should be measured directly, whereas fatigue is seen as a global outcome.

[1]  G. Yue,et al.  Cancer-related fatigue: central or peripheral? , 2009, Journal of pain and symptom management.

[2]  T. Furukawa,et al.  Factors correlated with fatigue in terminally ill cancer patients: a longitudinal study. , 2008, Journal of pain and symptom management.

[3]  P. Stone,et al.  Fatigue in palliative care patients — an EAPC approach , 2008, Palliative medicine.

[4]  M. C. Boruban,et al.  The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. , 2007, European journal of cancer care.

[5]  K. Courneya,et al.  Possible links between behavioral and physiological indices of tiredness, fatigue, and exhaustion in advanced cancer , 2008, Supportive Care in Cancer.

[6]  L. Oldervoll,et al.  Assessing physical functioning: a systematic review of quality of life measures developed for use in palliative care , 2007, Palliative medicine.

[7]  D. Osoba,et al.  Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Shaw,et al.  Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  I. Bosaeus,et al.  Daily Physical-Rest Activities in Relation to Nutritional State, Metabolism, and Quality of Life in Cancer Patients with Progressive Cachexia , 2007, Clinical Cancer Research.

[10]  I. Hickie,et al.  Postinfective fatigue syndrome is not associated with altered cytokine production. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  R. Skipworth,et al.  Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. , 2007, Journal of pain and symptom management.

[12]  P. Jean-Pierre,et al.  Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. , 2007, The oncologist.

[13]  M. Perlis,et al.  Cancer-related fatigue and sleep disorders. , 2007, The oncologist.

[14]  P. Jean-Pierre,et al.  Cancer-related fatigue: the scale of the problem. , 2007, The oncologist.

[15]  Kevin Fiscella,et al.  Mechanisms of cancer-related fatigue. , 2007, The oncologist.

[16]  H. Friess,et al.  Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia , 2007, Journal of Molecular Medicine.

[17]  E. Bruera,et al.  Palliative management of fatigue at the close of life: "it feels like my body is just worn out". , 2007, JAMA.

[18]  Nicholas F Taylor,et al.  Measuring muscle strength for people with chronic obstructive pulmonary disease: retest reliability of hand-held dynamometry. , 2007, Archives of physical medicine and rehabilitation.

[19]  E. Bruera,et al.  The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer , 2006, Cancer.

[20]  S. Kritchevsky,et al.  The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[21]  K. Chamari,et al.  Comparison of muscle mechanical and histochemical properties between young and elderly subjects. , 2006, International journal of sports medicine.

[22]  E. Bruera,et al.  Symptom control in palliative care--Part II: cachexia/anorexia and fatigue. , 2006, Journal of palliative medicine.

[23]  F. López‐Soriano,et al.  Muscle wasting in cancer and ageing: cachexia versus sarcopenia. , 2006, Advances in gerontology = Uspekhi gerontologii.

[24]  Romain Meeusen,et al.  Central Fatigue , 2006, Sports medicine.

[25]  Declan Walsh,et al.  Symptom clustering in advanced cancer , 2006, Supportive Care in Cancer.

[26]  S. Nadeau,et al.  Reliability and validity of static knee strength measurements obtained with a chair-fixed dynamometer in subjects with hip or knee arthroplasty. , 2005, Archives of physical medicine and rehabilitation.

[27]  D. Taillandier,et al.  The ubiquitin-proteasome system and skeletal muscle wasting. , 2005, Essays in biochemistry.

[28]  D. V. Von Hoff,et al.  A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  L. Saltz,et al.  Cetuximab therapy and symptomatic hypomagnesemia. , 2005, Journal of the National Cancer Institute.

[30]  M. Albitar,et al.  Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome , 2005, Cancer.

[31]  M. Tisdale The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. , 2005, The journal of supportive oncology.

[32]  E. Bruera,et al.  Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. McMillan,et al.  The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer , 2005, Cancer.

[34]  Dieter Felsenberg,et al.  Is muscle power output a key factor in the age‐related decline in physical performance? A comparison of muscle cross section, chair‐rising test and jumping power , 2004, Clinical physiology and functional imaging.

[35]  J. Tariman,et al.  Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. , 2004, Clinical journal of oncology nursing.

[36]  P. Fayers,et al.  The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors , 2003, Palliative medicine.

[37]  Eduardo Bruera,et al.  A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea , 2003, Palliative medicine.

[38]  Sharon L Olson,et al.  Test-retest strength reliability: hand-held dynamometry in community-dwelling elderly fallers. , 2002, Archives of physical medicine and rehabilitation.

[39]  C. Bing,et al.  Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans , 2002, British Journal of Cancer.

[40]  P. Stone,et al.  Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. , 2001, Journal of pain and symptom management.

[41]  Y. Nishiwaki,et al.  Fatigue in ambulatory patients with advanced lung cancer: prevalence, correlated factors, and screening. , 2001, Journal of pain and symptom management.

[42]  J. Davis,et al.  Serotonin and central nervous system fatigue: nutritional considerations. , 2000, The American journal of clinical nutrition.

[43]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[44]  F. Bozzetti,et al.  Effects of cachexia due to cancer on whole body and skeletal muscle protein turnover , 1998, Cancer.

[45]  D. Cella,et al.  Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. , 1997, Journal of pain and symptom management.